je.st
news
Tag: endpoints
AutoGrid announces compatibility with FLO | AddEnergie; flexible utility management of EV charging endpoints
2021-01-29 12:55:38| Green Car Congress
Tags: management
flexible
utility
compatibility
ICS Cybersecurity: Protecting the Industrial Endpoints That Matter Most
2017-09-11 23:10:00| Chemical Processing
With cyber incidents and reported vulnerabilities on the rise, industrial cybersecurity leaders must deploy proactive industrial endpoint detection and response (EDR) across the entire process control network including the proprietary industrial control systems and smart field instruments.This paper will examine how EDR should extend to proprietary endpoints, what security controls have the greatest effect on reducing risk for these cyber assets, and what best practices apply. Download Now
Tags: industrial
matter
protecting
ics
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Mercks ZEPATIER (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
2016-04-14 07:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head, the companys comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN/RBV) in treatment-nave and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infect Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
safety
treatment
trial
Firewall Products connect thousands of machine endpoints.
2016-03-07 14:31:05| Industrial Newsroom - All News for Today
With NextGen Firewall S-Series, customers can enforce proper access privileges, secure and centrally manage all communications, and roll out thousands of devices in remote locations. Series includes NextGen Firewall Secure Connector 1 (SC1), which provides firewalling, Wi-Fi, and full VPN connectivity. Consisting of virtual gateway, NextGen Secure Access Concentrator optimizes network traffic flow and centrally applies next-generation security functionality to deployed SC1 appliances.
Tags: products
machine
thousands
connect